Bacterial Aminopeptidase–Activated Peptide Prodrug Enables Species-Selective Targeting of Pseudomonas aeruginosa
Preprint
Abstract
Pseudomonas aeruginosa is an adaptable organism, frequently found in chronic infections, and for which antimicrobial resistance is a growing concern. Therefore, there is an urgent need for alternative therapeutic strategies. Cationic antimicrobial peptides (AMPs) offer potent bactericidal activity but suffer from limited selectivity and potential host toxicity. To enhance species-specific targeting, we designed two prodrug variants of the AMP D-Bac8C Leu2,5 – EEEE□-Bac8C Leu2,5 and ELE□ D-Bac8C Leu2,5 —engineered for activation by the P. aeruginosa extracellular aminopeptidase PaAP. While both prodrug motifs effectively neutralized the positive charge of D-Bac8C Leu2,5 and prevented DNA–peptide complex formation, EEEE□-Bac8C Leu2,5 showed negligible antimicrobial activity due to slow and incomplete activation. In contrast, ELEG□-Bac8C Leu2,5 underwent rapid PaAP□mediated activation, restoring bactericidal activity in planktonic cultures and biofilms. PaAP contributed significantly to complete prodrug activation, particularly within biofilms, where the accumulation of partially activated intermediates correlated with biphasic killing kinetics. The prodrug showed reduced activity against other ESKAPEE pathogens, demonstrating selective activation by P. aeruginosa . Experiments selecting resistant bacteria revealed distinct mutations in lipopolysaccharide biosynthesis pathways for D-Bac8C Leu2,5 and the prodrug, with limited cross□resistance. These findings establish aminopeptidase□activated AMP prodrugs as a promising approach for species□selective antimicrobial therapy and highlight the feasibility of exploiting bacterial enzymes for controlled antimicrobial peptide activation.Keywords
Funding Information
- Biotechnology and Biological Sciences Research Council (BB/X511183/)
- Biotechnology and Biological Sciences Research Council (BB/T017686/1)
- Research Ireland (20/COV/8470)
- Research Ireland (16/RI/3737)
- UK Research and Innovation (MR/T041811/1)
- UK Research and Innovation (MR/Z000378/1)
This publication has 53 references indexed in Scilit:
- Conditional Antimicrobial Peptide TherapeuticsACS Nano, 2022
- Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeuticsSignal Transduction and Targeted Therapy, 2022
- PEGylated Oligothioetheramide Prodrugs Activated by Host Serum ProteasesChemBioChem, 2021
- The value of antimicrobial peptides in the age of resistanceThe Lancet Infectious Diseases, 2020
- In Vivo Proteome of Pseudomonas aeruginosa in Airways of Cystic Fibrosis PatientsJournal of Proteome Research, 2019
- Photo‐Organocatalytic Enantioselective Radical Cascade Reactions of Unactivated OlefinsAngewandte Chemie International Edition, 2018
- Co-evolution with Staphylococcus aureus leads to lipopolysaccharide alterations in Pseudomonas aeruginosaThe ISME Journal, 2017
- Identification of Mutations in Laboratory-Evolved Microbes from Next-Generation Sequencing Data Using breseq2014
- Controlled Systemic Release of Therapeutic Peptides from PEGylated Prodrugs by Serum ProteasesAngewandte Chemie International Edition, 2013
- High-throughput generation of small antibacterial peptides with improved activityNature Biotechnology, 2005